Teduglutide (Gattex)
Overview
Teduglutide is a recombinant analogue of human glucagon-like peptide-2 (GLP-2) comprising 33 amino acids with a single amino acid substitution that confers resistance to enzymatic degradation by dipeptidyl peptidase-4. This GLP-2 receptor agonist enhances intestinal epithelial barrier function, promotes mucosal growth, and increases mesenteric blood flow, thereby improving nutrient and fluid absorption.
Mechanism of Action
The therapeutic rationale centers on reducing dependence on parenteral nutrition in patients with short bowel syndrome by augmenting remnant bowel adaptive capacity.
Research Summary & Key Findings
Teduglutide received FDA approval in 2012 for adults with short bowel syndrome dependent on parenteral support, based on pivotal phase 3 trial data published in Gastroenterology (2011) demonstrating significant reductions in parenteral nutrition volume. Pediatric approval followed in 2019 after the phase 3 trial results were published in JPEN (2017), confirming efficacy and safety in children aged one year and older.
Clinical Status
Teduglutide (Gattex) has received FDA approval and is available for clinical use under appropriate medical supervision. Consult a qualified healthcare provider for prescribing information.
Administration Routes
References
Primary literature
- PubMed — "Teduglutide"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov — "Teduglutide"
Registered interventional and observational studies, including status and phase.
- PubChem — "Teduglutide"
Chemical structure, molecular properties, and bioactivity data.
Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.
Related Peptides in Metabolic
Semaglutide (Ozempic/Wegovy)
FDA ApprovedA glucagon-like peptide-1 receptor agonist (GLP-1 RA) with 94% amino acid homology to native GLP-1. Semaglutide enhances...
View detailsTirzepatide (Mounjaro/Zepbound)
FDA ApprovedA first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. Tirzepatide activat...
View detailsRetatrutide
In Clinical TrialsAn investigational triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. The gluc...
View detailsAOD-9604
InvestigationalA modified 16-amino acid fragment (amino acids 176-191) of the C-terminus of human growth hormone with an added tyrosine...
View detailsStart Your Consultation
Get an AI-proposed Teduglutide (Gattex) protocol reviewed by a physician in our network.
Start Your ConsultationFind a Pharmacy
Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Teduglutide (Gattex).
Pharmacy DirectoryJoin the Association
Access exclusive peptide protocols, provider resources, and community support.
List Your PracticeDisclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.